Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Richard AC Clark"'
Autor:
Wallace J Brownlee, Christian Wolf, Hans-Peter Hartung, Theo Dingermann, Nadia Anshasi, Richard AC Clark, Maria Trojano, Krzysztof Selmaj, Bernard MJ Uitdehaag, Carmen Tur, Jens Wuerfel, Gabriele Dallmann, Julian Witte, Martina Sintzel, Olga Bobrovnikova, Jeffrey A Cohen
Publikováno v:
Multiple Sclerosis Journal, 28(14), 2177-2189. SAGE Publications Ltd
Brownlee, W J, Wolf, C, Hartung, H-P, Dingermann, T, Anshasi, N, Clark, R A C, Trojano, M, Selmaj, K, Uitdehaag, B M J, Tur, C, Wuerfel, J, Dallmann, G, Witte, J, Sintzel, M, Bobrovnikova, O & Cohen, J A 2022, ' Use of follow-on disease-modifying treatments for multiple sclerosis : Consensus recommendations ', Multiple Sclerosis Journal, vol. 28, no. 14, pp. 2177-2189 . https://doi.org/10.1177/13524585221116269
Brownlee, W J, Wolf, C, Hartung, H-P, Dingermann, T, Anshasi, N, Clark, R A C, Trojano, M, Selmaj, K, Uitdehaag, B M J, Tur, C, Wuerfel, J, Dallmann, G, Witte, J, Sintzel, M, Bobrovnikova, O & Cohen, J A 2022, ' Use of follow-on disease-modifying treatments for multiple sclerosis : Consensus recommendations ', Multiple Sclerosis Journal, vol. 28, no. 14, pp. 2177-2189 . https://doi.org/10.1177/13524585221116269
Background: As patents for multiple sclerosis (MS) therapies expire, follow-on disease-modifying treatments (FO-DMTs) become available at reduced cost. Concerns exist that cheaper FO-DMTs are used simply to reduce healthcare costs. However, the well-